News | March 25, 2026
FDA nod to Johnson & Johnson’s oral psoriasis therapy 'ICOTYDE'
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
New targeted pill offers hope for adults and teens with moderate-to-severe plaque psoriasis
It promises fewer injections for vision loss patients
The company plans to submit the vaccine for regulatory review
The company’s ACC lineup underscores a growing body of evidence backing the drug’s performance beyond controlled trials
The once-weekly treatment targets Type 2 Diabetes Mellitus (T2DM) with demonstrated efficacy and safety
The global, first-in-human, open-label trial will assess the safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity of TRI-611
The collaboration highlights the rising importance of intranasal delivery in developing non-vaccine approaches to respiratory disease prevention
Esprit is a multicenter, randomized, placebo-controlled, double-blind study assessing the safety, pharmacodynamics, and preliminary efficacy of S-606001 as a substrate reduction therapy
The announcement marks Dr. Reddy’s Day?1 entry into the GLP?1 receptor agonists therapy space and readiness to serve patients in India
The trial met its primary endpoint, with the combination therapy demonstrating a “statistically significant and clinically meaningful” improvement in radiographic progression-free survival
Subscribe To Our Newsletter & Stay Updated
